{
    "nct_id": "NCT04958226",
    "official_title": "An Open-label, Fixed-sequence Study to Assess the Effect of Repeated Doses of Capivasertib on the Pharmacokinetics of Oral Midazolam (a CYP450 3A Probe) in Patients With Advanced Solid Tumours",
    "inclusion_criteria": "1. Participants with documented evidence of locally advanced inoperable or metastatic solid tumours who may be suitable to receive capivasertib treatment.\n2. Eastern Cooperative Oncology Group/World Health Organization performance status 0 to 1 and with minimum life expectancy for 12 weeks.\n3. Participant should have at least one lesion that can be assessed by computed tomography/magnetic resonance imaging or plain X-ray at baseline.\n4. Body mass index within the range 18 to 32 kg/m^2\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 130 Years",
    "exclusion_criteria": "Participants are excluded from the study if any of the following criteria apply:\n\n1. Radiotherapy with a wide field of radiation within 4 weeks of the first dose of capivasertib and/or radiotherapy with a limited field of radiation for palliation within 2 weeks prior to study intervention initiation.\n2. Participants with diabetes mellitus type I or participants with diabetes mellitus type II requiring insulin treatment.\n3. Undergone a major surgery within 4 weeks of the first dose of capivasertib.\n4. Any unresolved toxicities from prior therapies higher than CTCAE grade 2 or any unresolved toxicity that may interfere with PK assessment at the time of study intervention initiation.\n5. Participants with spinal cord compression or brain metastases.\n6. Participants with severe or uncontrolled systemic diseases, active bleeding diatheses, or active infection.\n7. Previous allogeneic bone marrow transplant or solid organ transplant.\n8. Known immunodeficiency syndrome.",
    "miscellaneous_criteria": ""
}